BioPharmSignal logoBioPharmSignal

Biotech News

Immatics Announces $150 Million Underwritten Offering

Immatics (IMTX)ImmaticsFinancing

Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916

Related news

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-22 20:05 EST

Biomea Fusion Announces Proposed Public Offering of Securities

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

JNJJohnson & Johnson2026-08-21 09:40 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care

TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST

Teva Announces Launch of Offering of Senior Notes

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

View all latest news

Immatics

TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...

Recent company news

IMTXImmatics2026-08-25 11:00 EST

Immatics Announces $150 Million Underwritten Offering

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

IMTXImmatics2026-06-01 12:00 EST

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Stock data

Close
7.50 USD
Market cap
1.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States